ES2130574T3 - Agentes de restriccion de las citoquinas. - Google Patents

Agentes de restriccion de las citoquinas.

Info

Publication number
ES2130574T3
ES2130574T3 ES95902487T ES95902487T ES2130574T3 ES 2130574 T3 ES2130574 T3 ES 2130574T3 ES 95902487 T ES95902487 T ES 95902487T ES 95902487 T ES95902487 T ES 95902487T ES 2130574 T3 ES2130574 T3 ES 2130574T3
Authority
ES
Spain
Prior art keywords
cytokine
subject
agents
restriction agents
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95902487T
Other languages
English (en)
Inventor
Mark J Suto
Beverly E Girten
Richard A Houghten
Costas C Loullis
Ronald R Tuttle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trega Biosciences Inc
Original Assignee
Trega Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trega Biosciences Inc filed Critical Trega Biosciences Inc
Application granted granted Critical
Publication of ES2130574T3 publication Critical patent/ES2130574T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA NUEVOS AGENTES DE INHIBICION DE CITOQUINA, QUE LIMITAN O CONTROLAN LA ACTIVIDAD BIOLOGICA DE LAS CITOQUINAS. LA INVENCION TAMBIEN PROPORCIONA COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN UN PEPTIDO DE INHIBICION DE CITOQUINA Y METODOS DE ADMINISTRACION DE LA COMPOSICION FARMACEUTICA A UN INDIVIDUO. LA INVENCION ADEMAS PROPORCIONA METODOS PARA UTILIZAR LOS NUEVOS PEPTIDOS PARA INHIBIR LA ACTIVIDAD DE CITOQUINA EN UN INDIVIDUO.
ES95902487T 1993-11-12 1994-11-09 Agentes de restriccion de las citoquinas. Expired - Lifetime ES2130574T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/151,534 US5420109A (en) 1993-11-12 1993-11-12 Cytokine restraining agents

Publications (1)

Publication Number Publication Date
ES2130574T3 true ES2130574T3 (es) 1999-07-01

Family

ID=22539190

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95902487T Expired - Lifetime ES2130574T3 (es) 1993-11-12 1994-11-09 Agentes de restriccion de las citoquinas.

Country Status (14)

Country Link
US (3) US5420109A (es)
EP (1) EP0679092B1 (es)
JP (2) JP2793719B2 (es)
KR (1) KR100248033B1 (es)
AT (1) ATE179429T1 (es)
CA (1) CA2153584C (es)
DE (1) DE69418181T2 (es)
DK (1) DK0679092T3 (es)
ES (1) ES2130574T3 (es)
FI (1) FI953378A (es)
GR (1) GR3030382T3 (es)
NO (1) NO952744L (es)
NZ (1) NZ276906A (es)
WO (1) WO1995013086A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5741774A (en) * 1993-11-12 1998-04-21 Trega Biosciences, Inc. Use of a cytokine regulatory agent to treat rheumatoid arthritis
US5888978A (en) * 1995-09-12 1999-03-30 Trega Biosciences, Inc. Method for reducing the severity of gastro-intestinal damage
US6841533B1 (en) 1995-12-07 2005-01-11 Peptor Limited Conformationally constrained backbone cyclized interleukin-6 antagonists
IL130238A0 (en) * 1999-06-01 2000-06-01 Peptor Ltd Conformationally constrained backbone cyclized interleukin-6 antagonists
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US6045788A (en) * 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
AU4491697A (en) * 1996-09-27 1998-04-17 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
US20020197249A1 (en) * 2001-04-10 2002-12-26 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood products
US20020198487A1 (en) * 2001-04-10 2002-12-26 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in physiologic fluids
US8329388B2 (en) * 1997-07-30 2012-12-11 Cytosorbents, Inc. Biocompatible devices, systems, and methods for reducing levels of proinflammatory of antiinflammatory stimulators or mediators in the blood
US20020197250A1 (en) * 2001-04-10 2002-12-26 Renal Tech International Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
US20020159995A1 (en) * 1997-07-30 2002-10-31 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
US6723319B1 (en) 1998-03-17 2004-04-20 Chugai Seiyaku Kabushiki Kaisha Method of treating inflammatory intestinal diseases containing as the ingredient IL-6 receptors antibodies
US6284735B1 (en) 1998-04-28 2001-09-04 Lion Bioscience Ag HP-3228 and related peptides to treat sexual dysfunction
EP1076649A4 (en) 1998-04-28 2010-06-02 Trega Biosciences Inc ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
EP1593384A3 (en) * 1999-06-29 2006-04-26 Palatin Technologies, Inc. Compositions for treatment of sexual dysfunction
AU6605800A (en) * 1999-07-16 2001-02-05 Trega Biosciences, Inc. Melanocortin receptor-3 ligands to treat sexual dysfunction
US6921530B1 (en) 1999-09-24 2005-07-26 Cornell Research Foundation, Inc. Low dose IL-2 for potentiation of immunity
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6878127B2 (en) 2001-04-10 2005-04-12 Renaltech International, Llc Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
US8703146B2 (en) * 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
WO2002085933A1 (en) 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
CA2453515A1 (en) * 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US7067621B2 (en) * 2002-08-20 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Multifunctional context-activated protides and methods of use
AU2002950957A0 (en) * 2002-08-23 2002-09-12 The Walter And Eliza Hall Institute Of Medical Research A method of treatment and prophylaxis
JP4611738B2 (ja) * 2002-08-23 2011-01-12 ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 治療および予防の方法
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
FR2869531B1 (fr) * 2004-04-30 2006-07-14 Optis France Sa Sa Dispositif de iontophorese oculaire diminuant les irritations
EP1758598B1 (fr) * 2004-04-30 2016-04-13 Eyegate Pharma SAS Dispositif d'iontophorèse oculaire diminuant les irritations
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
TWI334784B (en) * 2006-04-14 2010-12-21 Buck Inst For Age Res Compositions and methods for suppression of amyloid plaque formation associated with neurodegenerative disorders
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
AU2009332951B2 (en) 2008-12-31 2015-06-11 Eyegate Pharmaceuticals, Inc. System and method for ocular iontophoresis with buffering
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
CN103096911B (zh) 2010-04-27 2018-05-29 Atyr 医药公司 与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6008837B2 (ja) 2010-04-28 2016-10-19 エータイアー ファーマ， インコーポレイテッド アラニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US9068177B2 (en) 2010-04-29 2015-06-30 Atyr Pharma, Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
AU2011248490B2 (en) 2010-04-29 2016-11-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CA2797978C (en) 2010-05-03 2019-12-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
CN103096912A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2797277C (en) 2010-05-03 2021-02-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
AU2011248101B2 (en) 2010-05-04 2016-10-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
CN103200953B (zh) 2010-05-14 2017-02-15 Atyr 医药公司 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
WO2011153277A2 (en) 2010-06-01 2011-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
EP2593125B1 (en) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
EP2608801B1 (en) 2010-08-25 2019-08-21 aTyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
MX356107B (es) 2012-02-16 2018-05-15 Atyr Pharma Inc Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
WO2016073897A1 (en) 2014-11-06 2016-05-12 Northwestern University Inhibition of cancer cell motility
AU2018256435A1 (en) 2017-04-20 2019-11-07 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457864A (en) * 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) * 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
US4649191A (en) * 1984-05-10 1987-03-10 Gibson-Stephens Neuropharmaceuticals, Inc. Conformationally constrained alpha-melanotropin analogs with specific central nervous system activity
US5157023A (en) * 1984-08-21 1992-10-20 Lipton James M Antipyretic and anti-inflammatory lys pro val compositions and method of use
US5028592A (en) * 1986-08-08 1991-07-02 Lipton James M Antipyretic and anti-inflammatory peptides
WO1987004623A1 (en) * 1986-02-03 1987-08-13 University Patents, Inc. Method of stimulating melanocytes by topical application of analogs of alpha-msh, and compositions for use in same
EP0292291B1 (en) * 1987-05-22 1994-08-10 University Patents, Inc. Linear and cyclic analogs of alpha-msh fragments with extraordinary potency
EP0293837B1 (en) * 1987-06-01 1992-01-15 Keikichi Sugiyama Composition for application to hair or scalp
US5049547A (en) * 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US5114960A (en) * 1989-07-20 1992-05-19 Hoffmann-La Roche Inc. Substituted isoxazole derivatives
ZA908610B (en) * 1989-11-03 1991-08-28 Univ Tulane Peptides aiding nerve regeneration
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5741774A (en) * 1993-11-12 1998-04-21 Trega Biosciences, Inc. Use of a cytokine regulatory agent to treat rheumatoid arthritis
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels

Also Published As

Publication number Publication date
CA2153584C (en) 2000-05-09
EP0679092A4 (en) 1997-11-19
KR100248033B1 (ko) 2000-04-01
CA2153584A1 (en) 1995-05-18
DK0679092T3 (da) 1999-11-08
EP0679092B1 (en) 1999-04-28
DE69418181D1 (de) 1999-06-02
DE69418181T2 (de) 1999-12-23
US6245738B1 (en) 2001-06-12
ATE179429T1 (de) 1999-05-15
WO1995013086A1 (en) 1995-05-18
NO952744L (no) 1995-09-08
JP3357883B2 (ja) 2002-12-16
GR3030382T3 (en) 1999-09-30
FI953378A0 (fi) 1995-07-10
AU678329B2 (en) 1997-05-22
NO952744D0 (no) 1995-07-11
AU1174195A (en) 1995-05-29
US5888969A (en) 1999-03-30
US5420109A (en) 1995-05-30
JPH08508299A (ja) 1996-09-03
JPH10259196A (ja) 1998-09-29
EP0679092A1 (en) 1995-11-02
NZ276906A (en) 1997-05-26
JP2793719B2 (ja) 1998-09-03
FI953378A (fi) 1995-07-10

Similar Documents

Publication Publication Date Title
ES2130574T3 (es) Agentes de restriccion de las citoquinas.
CA2189250A1 (en) Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
ES2151467T1 (es) Inhibicion de la actividad de la quinasa p38 por aril-ureas.
DK0708772T3 (da) Imidazo[4,5,-c]pyridin-4-aminer
HK1097449A1 (en) Methods for in vivo delivery of biologics and compositions useful therefor
ES2155817T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
ES2154253T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas.
TR199802423T2 (xx) Konsantre antikor terkibi.
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
NO954722L (no) Peptid inhibitorer med urokinase reseptoraktivitet
ATE245977T1 (de) Therapeutische substituierte guanidine
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
DE69520475D1 (de) Pharmaceutische Zusammensetzung von biologisch aktiven Peptiden oder Proteinen
FR2694296B1 (fr) Peptides inhibant l'activité des protéines ras, préparation et utilisation.
BR0312889A (pt) Polipeptìdeo t20 peguilado
MX9204240A (es) Montaje distribuidor y de mezclado de dos etapas para preparaciones tal como cementos dentales.
DK403384D0 (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
DE3773295D1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
DK0719276T3 (da) Ïstradiolestre med stærk oral virkning samt farmaceutiske præparater med indhold deraf
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
DE69626050D1 (de) Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE69434151D1 (de) Therapeutische inhaltsstoffe
NZ217356A (en) Benzamide derivatives and pharmaceutical compositions

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 679092

Country of ref document: ES